- Home
- About Us
- Industry
- Services
- Reading
- Contact Us
Nucleic Acid Amplification Testing Market: Current Analysis and Forecast (2025-2033)
Emphasis on Technology (Polymerase Chain Reaction (PCR) Tests, Isothermal Nucleic Acid Amplification Technology (INAAT) Tests, Ligase Chain Reaction (LCR) Tests, and Others); Application (Infectious Disease Testing, Oncology Testing, Genetic Testing, and Others); End-User (Hospitals and Clinics, Diagnostic Centers, Academic and Government Institutes, and Others); and Region/Country
Global Nucleic Acid Amplification Testing Market Size & Forecast
The Global Nucleic Acid Amplification Testing Market was valued at USD 9,040 million in 2024 and is expected to grow at a strong CAGR of around 10.58% during the forecast period (2025-2033F), driven by the rising prevalence of infectious diseases such as COVID-19, tuberculosis, and STIs, necessitating accurate and early diagnosis.
Nucleic Acid Amplification Testing Market Analysis
Nucleic Acid Amplification Testing (NAAT) is a laboratory technique of molecular diagnostics serving as a method of detecting the existence of particular genetic material (DNA or RNA) of a pathogen, viruses, bacteria, or other microorganisms. It can be used to amplify small amounts of nucleic acid to detectable levels, then identify the early and accurate diagnosis of infectious diseases, genetic diseases, and some cancer diseases. The market for Nucleic Acid Amplification Testing (NAAT) is boosted by the fact that the world has been experiencing an increasing need for accurate, fast, and early diagnosis of infectious diseases, such as COVID-19, HIV, tuberculosis, and STIs.
Global Nucleic Acid Amplification Testing Market Trends
This section discusses the key market trends that are influencing the various segments of the global nucleic acid amplification testing market, as found by our team of research experts.
Rising demand for non-invasive and self-collected sampling kits
The increased preference for non-invasive and self-collected sampling kits is an emerging trend in the Nucleic Acid Amplification Testing (NAAT) market, as these methods are more convenient, private, and easy to use, making them highly attractive for mass screening and in-home diagnostics. They also minimize the number of clinic visits and trained healthcare staff, leading to a decrease in the total cost of healthcare procedures and testing. Self-collection activities were boosted by consumers during the COVID-19 pandemic and contributed to the acceleration of the development of self-collection activities. With personalized medicine and preventive care becoming prevalent, there is a high possibility that the demand for easy-to-use and non-invasive diagnostic devices and solutions will increase vastly.
For instance, in March 2025, Visby Medical™, which is a leading innovator in medical diagnostics, announced that the U.S. Food and Drug Administration (FDA) had granted De Novo authorization for the Visby Medical Women’s Sexual Health Test for over-the-counter (OTC) use. This groundbreaking test enables reliable, rapid, and private at-home testing for Chlamydia, Gonorrhea, and Trichomoniasis, the three most common curable sexually transmitted infections (STIs).
Nucleic Acid Amplification Testing Industry Segmentation
This section provides an analysis of the key trends in each segment of the global nucleic acid amplification testing market report, along with forecasts at the global, regional, and country levels for 2025-2033.
The PCR Testing Technology Segment dominates the Global Nucleic Acid Amplification Testing Market
Based on the technology category, the market is categorized into PCR Tests, INAAT Tests, LCR Tests, and Others. Out of these, the PCR tests currently hold the largest market share in the NAAT market because of their high accuracy and sensitivity, along with popularity in clinical diagnostics. However, Isothermal Nucleic Acid Amplification Technology (INAAT) tests are expected to witness the fastest growth in the coming years, due to the properties of providing results with high speed, without requiring thermal cycling.
The Infectious Disease Testing Segment dominates the Global Nucleic Acid Amplification Testing Market.
Based on the application category, the market is categorized into infectious disease testing, oncology testing, genetic testing, and others. Among these, the infectious disease testing holds the largest share in the NAAT market, because of the extensive global burden expected to be caused by infectious diseases and the potential of NAAT in early diagnosis and outbreak control. However, genetic testing is expected to witness the fastest growth in the coming years, due to the growing trend of personalized medicine, awareness of hereditary diseases, and the overall improvement in the genomic industry.
The North America region dominates the Global Nucleic Acid Amplification Testing Market.
North America holds the highest market share in the global nucleic acid amplification testing (NAAT) Market, owing to the very high healthcare expenditure, sophisticated healthcare infrastructure, and early adoption of novel technologies in diagnostics. Strong research and development, extensive application of molecular diagnostics, and availability of major biotechnology and pharmaceutical institutes are some of the advantages enjoyed by the region. Moreover, the increasing prevalence of infectious diseases, cancer, and genetic defects stimulates the demand for proper and quick ways of testing. Additionally, favourable regulations, greater awareness of healthcare providers, and well-established reimbursement policies are also beneficial in advancing the application of NAAT.
The United States held a Dominant share of the North America Nucleic Acid Amplification Testing Market in 2024
The United States is a major manufacturer in the North American Nucleic Acid Amplification Testing (NAAT) Market, as the United States is considered the leader in biotechnology innovation, early regulatory authorization, and broad adoption of NAAT into clinical practice. The active efforts of the country in controlling infectious diseases surveillance, including the efforts of the CDC and the NIH, led to speeding up the implementation of high-throughput molecular diagnostics in hospitals and state health labs. Also, robust investment in precision medicine and decentralized testing systems met the need to introduce rapid and reliable NAAT platforms.
Nucleic Acid Amplification Testing Industry Competitive Landscape
The global nucleic acid amplification testing market is competitive, with several global and international market players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, geographical expansions, and mergers and acquisitions.
Top Nucleic Acid Amplification Testing Market Companies
Some of the major players in the market are F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Agilent Technologies, Inc., Thermo Fisher Scientific Inc., Promega Corporation, Abbott Laboratories, GENOMTEC, Hologic, Inc., Ustar Biotechnologies, and SD Biosensor, Inc.
Recent Developments in the Nucleic Acid Amplification Testing Market
In May 2025– SynOligo Biotechnologies and Lumiphore announced a partnership to provide time-resolved luminescent oligos and assays for the nucleic acid amplification testing market (NAAT). The partnership aims to provide game-changing luminescent lanthanide-based oligo probes for diagnostics and life science research applications.
In July 2024, Roche announced the acquisition of LumiraDx’s Point of Care technology to enhance its product portfolio in the diagnostics segment. Through this acquisition, Roche complements its diagnostics portfolio with a simple-to-use platform that consolidates a wide range of immunoassay and clinical chemistry tests on a single instrument, with the future potential to expand into molecular testing.
Global Nucleic Acid Amplification Testing Market Report Coverage
Details | |
Base year | 2024 |
Forecast period | 2025-2033 |
Growth momentum | Accelerate at a CAGR of 10.58% |
Market size 2024 | USD 9,040 million |
Regional analysis | North America, Europe, APAC, Rest of the World |
Major contributing region | The Asia-Pacific region is expected to dominate the market during the forecast period. |
Key countries covered | U.S., Canada, Germany, U.K., Spain, Italy, France, China, Japan, South Korea, and India. |
Companies profiled | F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Agilent Technologies, Inc., Thermo Fisher Scientific Inc., Promega Corporation, Abbott Laboratories, GENOMTEC, Hologic, Inc., Ustar Biotechnologies, and SD Biosensor, Inc. |
Report Scope | Market Trends, Drivers, and Restraints; Revenue Estimation and Forecast; Segmentation Analysis; Demand and Supply Side Analysis; Competitive Landscape; Company Profiling |
Segments Covered | By Technology, By Application, By End-User, By Region/Country |
Reasons to Buy the Nucleic Acid Amplification Testing Market Report:
The study includes market sizing and forecasting analysis confirmed by authenticated key industry experts.
The report briefly reviews overall industry performance at a glance.
The report covers an in-depth analysis of prominent industry peers, primarily focusing on key business financials, type portfolios, expansion strategies, and recent developments.
Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.
The study comprehensively covers the market across different segments.
Deep dive regional level analysis of the industry.
Customization Options:
The Global Nucleic Acid Amplification Testing Market can further be customized as per the requirements or any other market segment. Besides this, UnivDatos understands that you may have your own business needs; hence, feel free to contact us to get a report that completely suits your requirements.
Table of Content
Research Methodology for the Global Nucleic Acid Amplification Testing Market Analysis (2023-2033)
We analyzed the historical market, estimated the current market, and forecasted the future market of the global nucleic acid amplification testing market to assess its application in major regions worldwide. We conducted exhaustive secondary research to gather historical market data and estimate the current market size. To validate these insights, we carefully reviewed numerous findings and assumptions. Additionally, we conducted in-depth primary interviews with industry experts across the nucleic acid amplification testing value chain. After validating market figures through these interviews, we used both top-down and bottom-up approaches to forecast the overall market size. We then employed market breakdown and data triangulation methods to estimate and analyze the market size of industry segments and sub-segments.
Market Engineering
We employed the data triangulation technique to finalize the overall market estimation and derive precise statistical numbers for each segment and sub-segment of the global nucleic acid amplification testing market. We split the data into several segments and sub-segments by analyzing various parameters and trends, including technology, application, end-user, and regions within the global nucleic acid amplification testing market.
The Main Objective of the Global Nucleic Acid Amplification Testing Market Study
The study identifies current and future trends in the global nucleic acid amplification testing market, providing strategic insights for investors. It highlights regional market attractiveness, enabling industry participants to tap into untapped markets and gain a first-mover advantage. Other quantitative goals of the studies include:
Market Size Analysis: Assess the current and forecast market size of the global nucleic acid amplification testing market and its segments in terms of value (USD).
Nucleic Acid Amplification Testing Market Segmentation: Segments in the study include areas of technology, application, end-user, and region.
Regulatory Framework & Value Chain Analysis: Examine the regulatory framework, value chain, customer behavior, and competitive landscape of the nucleic acid amplification testing industry.
Regional Analysis: Conduct a detailed regional analysis for key areas such as Asia Pacific, Europe, North America, and the Rest of the World.
Company Profiles & Growth Strategies: Company profiles of the nucleic acid amplification testing market and the growth strategies adopted by the market players to sustain the fast-growing market.
Frequently Asked Questions FAQs
Q1: What is the global nucleic acid amplification testing market’s current market size and growth potential?
As of 2024, the global nucleic acid amplification testing market is valued at USD 9,040 million and is projected to grow at a CAGR of around 10.58% from 2025 to 2033. This growth is fueled by increasing demand for rapid, accurate diagnostics in infectious diseases, genetic testing, and oncology applications.
Q2: Which segment has the largest share of the global nucleic acid amplification testing market by technology category?
The Polymerase Chain Reaction (PCR) testing segment holds the largest market share in the global NAAT market. PCR is widely used due to its high accuracy, sensitivity, and reliability in detecting various pathogens, making it a gold standard in molecular diagnostics for infectious diseases and genetic disorders.
Q3: What are the driving factors for the growth of the global nucleic acid amplification testing market?
The NAAT market is driven by the rising prevalence of infectious diseases such as COVID-19, tuberculosis, and sexually transmitted infections (STIs). Increasing demand for early, accurate diagnosis, coupled with advancements in molecular diagnostic technologies and growing healthcare investments, is accelerating market expansion globally.
Q4: What are the emerging technologies and trends in the global nucleic acid amplification testing market?
Emerging trends in the Nucleic Acid Amplification Testing market include the development of portable and point-of-care NAAT devices, which enable faster results outside laboratory settings. Additionally, the integration of AI and digital health platforms, multiplex testing, and cloud-based diagnostics is revolutionizing how NAAT is used in clinical and remote healthcare environments.
Q5: What are the key challenges in the global nucleic acid amplification testing market?
Key challenges in the global NAAT market include the high cost of testing instruments and reagents, making it difficult for widespread adoption in low-resource settings. Other barriers include limited access to trained personnel, lack of diagnostic infrastructure in rural areas, and regulatory complexities in emerging markets.
Q6: Which region dominates the global nucleic acid amplification testing market?
North America dominates the global NAAT market, driven by advanced healthcare infrastructure, high testing volumes, strong presence of leading diagnostic companies, and substantial R&D investments. The region's proactive disease surveillance efforts and early adoption of cutting-edge diagnostics continue to support its market leadership.
Q7: Who are the key competitors in the global Nucleic Acid Amplification Testing market?
Top players in the Nucleic Acid Amplification Testing industry include:
• F. Hoffmann-La Roche Ltd.
• Bio-Rad Laboratories
• Agilent Technologies, Inc.
• Thermo Fisher Scientific Inc.
• Promega Corporation
• Abbott Laboratories
• GENOMTEC
• Hologic, Inc.
• Ustar Biotechnologies
• SD Biosensor, Inc.
Q8: What are the key investment opportunities in the global nucleic acid amplification testing (NAAT) market?
Key investment opportunities in the NAAT market lie in the development of cost-effective point-of-care diagnostic solutions, automation, and AI integration, and expansion into emerging markets with rising demand for molecular diagnostics. Strategic collaborations, R&D funding, and product innovation targeting oncology and personalized medicine also present attractive avenues for investors and companies.
Q9: How can diagnostic companies and healthcare providers leverage NAAT to enhance service offerings?
Diagnostic companies and healthcare providers can leverage NAAT to offer faster, more accurate, and comprehensive diagnostic services, particularly in infectious diseases, oncology, and genetic testing. By adopting portable NAAT platforms, integrating digital health solutions, and targeting underserved regions, they can improve patient outcomes and expand their market reach.
Related Reports
Customers who bought this item also bought
Nucleic Acid Amplification Testing Market: Current Analysis and Forecast (2025-2033)
Emphasis on Technology (Polymerase Chain Reaction (PCR) Tests, Isothermal Nucleic Acid Amplification Technology (INAAT) Tests, Ligase Chain Reaction (LCR) Tests, and Others); Application (Infectious Disease Testing, Oncology Testing, Genetic Testing, and Others); End-User (Hospitals and Clinics, Diagnostic Centers, Academic and Government Institutes, and Others); and Region/Country
August 5, 2025
KSA Hospital Market: Current Analysis and Forecast (2025-2033)
Emphasis on Hospital Ownership (Public Hospitals (Ministry of Health), Private Hospitals, Quasi-Government Hospitals); Bed Capacity (Up to 100 Beds, 100–500 Beds, More than 500 Beds); Hospital Type (General Hospitals, Specialty Hospitals, Multi-Specialty Hospitals); Service Type (In-Patient Services, Out-Patient Services)
June 9, 2025
